A consortium of investors, including EVX Ventures, Simcere Pharmaceuticals, Huagai Capital, and Cystic Fibrosis Foundation led a Series A round in Carmine Therapeutics, a biotech company. Financial terms were not disclosed. "We are thrilled to join Carmine family. As an early-stage investor in biotech industry, we value Carmine's RBCEV platform as a novel and advantageous delivery system in gene therapies, especially considering its payload capacity, costs, and safety. Combined with Carmine's patented payload engineering methods, we believe Carmine would bring patients with promising curative therapies. We are delighted to join the exciting journey, and join XQ, Don and the wonderful Carmine team led by Don," Deng Liang, Huagai Capital Partner.